Acceder Registro /

Jose Maria MORALEDA JIMÉNEZ

Buscador

Velez-Pinto JF, Garcia-Arranz M, Garcia-Bernal D, Garcia Gomez-Heras S, Villarejo-Campos P, Garcia-Hernandez AM, Vega-Clemente L, Jimenez-Galanes S, Guadalajara H, Moraleda JM, Garcia-Olmo D. Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model of abdominal sepsis. Stem Cell Res Ther. 2023 Dec 12;14(1):365. doi: 10.1186/s13287-023-03588-x. PubMed PMID: 38087374; PubMed Central PMCID: PMC10717819.
AÑO: 2023; IF: 7.5
Sanchez-Villalobos M, Campos Banos E, Juan Fita MJ, Egea Mellado JM, Gonzalez Gallego I, Beltran Videla A, Berenguer Piqueras M, Bermudez Cortes M, Moraleda Jimenez JM, Guillen Navarro E, Salido Fierrez E, Perez-Oliva AB. A Newborn Screening Program for Sickle Cell Disease in Murcia (Spain). Int J Neonatal Screen. 2023 Oct 10;9(4):55. doi: 10.3390/ijns9040055. PubMed PMID: 37873846; PubMed Central PMCID: PMC10594431.
AÑO: 2023
Liarte S, Bernabe-Garcia A, Rodriguez-Valiente M, Moraleda JM, Castellanos G, Nicolas FJ. Amniotic Membrane Restores Chronic Wound Features to Normal in a Keratinocyte TGF-beta-Chronified Cell Model. Int J Mol Sci. 2023 Mar 25;24(7):6210. doi: 10.3390/ijms24076210. PubMed PMID: 37047181; PubMed Central PMCID: PMC10094701.
AÑO: 2023; IF: 5.6
Tilmont R, Yakoub-Agha I, Eikema DJ, Zinger N, Haenel M, Schaap N, Arroyo CH, Schuermans C, Besemer B, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson KMO, Bourhis JH, Mateos MV, Rabin N, Jost E, Kroger N, Moraleda JM, Za T, Hayden PJ, Beksac M, Mclornan D, Schonland S, Manier S. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023 Nov;58(11):1182-1188. doi: 10.1038/s41409-023-02048-7. Epub 2023 Aug 5. PubMed PMID: 37543712; PubMed Central PMCID: PMC10622318.
AÑO: 2023; IF: 4.8
Oliver-Caldes A, Gonzalez-Calle V, Cabanas V, Espanol-Rego M, Rodriguez-Otero P, Reguera JL, Lopez-Corral L, Martin-Antonio B, Zabaleta A, Inoges S, Varea S, Rosinol L, Lopez-Diaz de Cerio A, Tovar N, Jimenez R, Lopez-Parra M, Rodriguez-Lobato LG, Sanchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Perez-Simon JA, Paiva B, Prosper F, Saez-Penataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernandez de Larrea C. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. PubMed PMID: 37414060.
AÑO: 2023; IF: 51.1

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R